Aim Immunotech Inc. (AIM) Stock Price & Analysis
Aim Immunotech Inc. (AIM) fell 0.40% to USD 0.25 as of July 25, 2026 at 07:00 UTC, according to Nexqual real-time market data.
AIM last closed at USD 0.25; the session ranged USD 0.24–0.25 on volume of 255,815 shares. Market capitalization is $6.90M, with a 52-week range of USD 0.21–19.74 (ASE). Source: Nexqual, July 25, 2026 at 07:00 UTC.
Key Statistics (as of July 25, 2026 at 07:00 UTC)
| Price | USD 0.25 |
|---|---|
| Change | ▼ 0.40% (down) |
| Previous Close | USD 0.25 |
| Open | USD 0.24 |
| Day Range | USD 0.24 – 0.25 |
| 52-Week Range | USD 0.21 – 19.74 |
| Volume | 255,815 shares |
| Market Cap | $6.90M |
| Exchange | ASE |
Technical Analysis (AIM)
Nexqual's technical model rates AIM "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 07:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 26.4 (oversold) |
| vs SMA50 | Below (USD 0.36) |
| MACD | -0.04 (negative) |
Analyst Ratings (AIM)
Wall Street analysts rate AIM "None" based on 2 analysts, with a mean price target of USD 5.25 (range USD 1.5–9), per Nexqual as of July 25, 2026 at 07:00 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 5.25 |
| High Target | USD 9 |
| Low Target | USD 1.5 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (AIM)
| EPS Estimate | USD -0.12 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.69 vs est -0.37 ▼ miss |
| 2025-12-31 | USD -0.44 vs est -0.94 ▲ beat |
| 2025-09-30 | USD -1.57 vs est -0.98 ▼ miss |
| 2025-06-30 | USD -3.68 vs est -7.99 ▲ beat |
Source: Nexqual, July 25, 2026 at 07:00 UTC.
Financials & Fundamentals (AIM)
| Total Revenue | $94,000 |
|---|---|
| Revenue Growth (YoY) | +37.50% |
| Gross Margin | -29.79% |
| Operating Margin | -10118.18% |
| Profit Margin | +0.00% |
| Debt / Equity | 215.25 |
| Current Ratio | 1.01 |
| Total Cash | $5.88M |
| Total Debt | $4.57M |
| Free Cash Flow | $-12.23M |
Source: Nexqual, July 25, 2026 at 07:00 UTC.
Financial Health Score (AIM)
Nexqual rates Aim Immunotech Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 07:00 UTC.
| Growth | Critical — Revenue -48% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $6M cash vs $5M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$12M, burning cash |
| Efficiency | Mixed — No data |
Ownership (AIM)
| Insider Ownership | +0.59% |
|---|---|
| Institutional Ownership | +0.75% |
| Shares Outstanding | 27.72M |
| Float | 12.75M |
| Short % of Float | +5.60% |
Source: Nexqual, July 25, 2026 at 07:00 UTC.
Leadership (AIM)
Aim Immunotech Inc. is led by Thomas K. Equels Esq., J.D., M.S. (age 72), Executive Vice Chairman, CEO & President, per Nexqual as of July 25, 2026 at 07:00 UTC.
| Executive Vice Chairman, CEO & President | Thomas K. Equels Esq., J.D., M.S. (age 72) |
|---|---|
| Chief Financial Officer | Robert Dickey IV, B.A. (age 69) |
| COO, Executive Director of Governmental Relations, General Counsel & Secretary | Peter W. Rodino III, Esq. (age 74) |
| Director of Administration & Human Resources and Deputy Investor Relations Coordinator | Ann Marie E. Coverly |
From Aim Immunotech Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Partnerships
- Kellner is a Chartered Financial Analyst with over 50 years of investment experience and currently manages his personal and family investments after retiring in 2017 from his career as a portfolio manager at Fiduciary Management, Inc., an investment management firm that he founded in 1980.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AYTU | Aytu BioPharma, Inc. | USD 2.16 | ▲ 0% |
| CODX | Co-Diagnostics, Inc. | USD 2.1 | ▼ 7.89% |
| IBIO | iBio, Inc. | USD 1.43 | ▲ 3.62% |
| COCP | Cocrystal Pharma, Inc. | USD 0.9 | ▼ 4.24% |
| NNVC | NanoViricides, Inc. | USD 1.48 | ▼ 2.63% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:00 UTC. This page is informational and not investment advice.